Luminex Teams With Merck For Alzheimer’s Companion Diagnostic
This article was originally published in The Gray Sheet
The assay will be used to support patient selection as part of Merck’s ongoing clinical trial program for the MK-8931 Alzheimer’s disease drug candidate.
You may also be interested in...
News Briefs: FDA Turns Down Wright’s Augment; Cook Resumes Zilver PTX Shipments; Luminex Restructures
Wright Medical receives not approvable letter for its Augment bone graft asking for another study. Judge rules against Zimmer in favor of Strkyer in patent case. Cook Medical has resolved the problems that triggered a December 2012 recall of its Zilver PTX peripheral stent. Luminex cuts staff, invests in molecular diagnostics efforts.
Merck will use GE Healthcare’s investigational positron emission tomography agent flutemetamol to select patients to enroll in clinical trials for its Alzheimer’s disease drug candidate.
Attention must be paid when withdrawal is for NDA approved in 1948 for brand synonymous with nonprescription pain relief, Bufferin. Even when FDA’s decision amounts to NDA database recordkeeping, withdrawal of application demands notice in US OTC space.